Atsena Therapeutics Announces 6-Month Data from Phase 1/2 Clinical Trial of ATSN-101 to be Presented at ARVO

Atsena Therapeutics announced that 6-month safety and efficacy data from the ongoing phase 1/2 clinical trial of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1) will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting, which is being held April 23-27 in New Orleans, LA.

LCA1 is a monogenic eye disease that disrupts the function of the retina and results in early and severe vision impairment or blindness. According to previously reported interim data from the phase 1/2 clinical trial, ATSN-101 has demonstrated clinically meaningful improvements in vision with no drug-related serious adverse events.

Details of the oral presentation are as follows:

Title: Six-month safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1)
Presentation Number: 1914
Session: Advances in gene therapy and gene editing for ocular diseases 1
Date / Time: Monday, April 24, 3:45 – 4:00 p.m. CT
Location: Ernest N. Morial Convention Center, R07-R08
Presenter: Christine Nichols Kay, MD, Atsena Therapeutics

In addition, Atsena is sponsoring and participating in the Retinal Cell and Gene Therapy Innovation Summit 2023, jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University (OHSU) Casey Eye Institute, which is being held on Friday, April 21 in New Orleans, LA.